ERAS
Erasca·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ERAS
Erasca, Inc.
A clinical-stage precision oncology company that develops therapies for RAS/MAPK pathway-driven cancers
3115 Merryfield Row, Suite 300, San Diego, CA 92121
--
Erasca, Inc., was incorporated in Delaware on July 2, 2018. The company is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for cancer patients driven by the RAS/MAPK pathway. Co-founded by leading pioneers in precision oncology and RAS targeting, the company aims to create new therapies and combination programs aimed at completely shutting down the RAS/MAPK pathway to treat cancer.
Company Financials
EPS
ERAS has released its 2025 Q3 earnings. EPS was reported at -0.11, versus the expected -0.1, missing expectations. The chart below visualizes how ERAS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
